Tag: AVG
EVA meeting unveils new data and global perspectives to boost vascular...
The third EVA Meeting (23–24 June, Patras, Greece) sought to build on international collaboration and science, one of the stated aims of the meeting...
WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study completes enrolment
Merit Medical has announced that is has completed enrolment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective,...
Renal Interventions’ top 10 stories of March 2023
The month of March brought PAVE-2 updates, preservation debates and an assessment of the best options in marginal veins. A series of transplant updates,...
Age ceiling for AVF “should be adjusted upwards”
Led by Hyangkyoung Kim (Ewha Womans University Medical Center, Seoul, South Korea) and featuring corresponding author Hoon Suk Park (The Catholic University of Korea...
AVGs “a better choice” than AVF when veins are marginal
A new study in the Journal of Vascular Access (JVA) has found that, while arteriovenous fistulas (AVFs) that do not require assistance to mature...
KDOQI vascular access guidelines: Opportunity or concern for clinical research?
Earlier this year, in an interview with Renal Interventions, Scott Trerotola (Philadelphia, USA) remarked that “guidelines are a research workbook for the next generation”....
Arteriovenous graft use linked to venous thromboembolism risk in haemodialysis patients
In an observational cohort study of Medicare beneficiaries receiving haemodialysis, the use of an arteriovenous graft (AVG) compared with an arteriovenous fistula (AVF) was...
Matteo Tozzi
Having grown up and studied medicine in Rome, Matteo Tozzi is currently deputy head of the Department of Medicine and Surgery, and associate professor...
A raft of new directions for vascular access grafts
A departure from the “extreme mantra” of Fistula First unlocks the door to a new, dynamic vision that could swing the pendulum back to...
Not always ‘the alternative’: Are arteriovenous grafts unfairly maligned?
The arteriovenous graft (AVG) for use as a dialysis conduit is a story of innovation, disappointment, intrigue, politics and hope. A recent recalibration of...
InnAVasc gains FDA nod for third study phase of investigational haemodialysis...
As per an announcement on the company’s LinkedIn page, InnAVasc Medical has been granted US Food and Drug Administration (FDA) permission to commence the...
Xeltis initiates European first-in-human trial of restorative haemodialysis access graft
Xeltis has announced initiation of a clinical trial evaluating Axess, which it claims is the first ever restorative synthetic haemodialysis access graft. Several patients...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF
Concept Medical has provided an update on the progress of the IMPRESSION (sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis access dysfunction)...
Treating steal syndrome: Symptoms, flow rate and anastomosis location all key...
When it comes to treating steal syndrome, the extent to which the dialysis patient in question is displaying symptoms—as well as their flow rate...